Sneha Anand
Postdoctoral Scientist
Sneha is currently a postdoctoral scientist in the Cellular High Content Imaging Group led by Daniel Ebner at the Target Discovery Institute (TDI), Centre for Medicines Discovery, University of Oxford. Sneha is responsible for cell-based high-throughput functional genomic screens. Before joining TDI, Sneha worked in Prof. Terry Rabbitt’s group at University of Oxford, where she worked on establishing technologies to target cellular protein function using antibody fragments as drug surrogates. She has experience developing specific and potent reagents to study cancer development and drug-like molecules as leads for therapeutic drug development. Sneha also holds a PhD in infection biology focusing on vaccine development for infectious diseases.
Recent publications
-
Phenotype execution and modeling architecture to support disease surveillance and real-world evidence studies: English sentinel network evaluation.
Journal article
Jamie G. et al, (2024), JAMIA Open, 7
-
AZD1222 effectiveness against severe COVID-19 in individuals with comorbidity or frailty: The RAVEN cohort study.
Journal article
Meeraus W. et al, (2024), J Infect, 88
-
Risk of severe COVID-19 outcomes after autumn 2022 COVID-19 booster vaccinations: a pooled analysis of national prospective cohort studies involving 7.4 million adults in England, Northern Ireland, Scotland and Wales.
Journal article
Bedston S. et al, (2024), Lancet Reg Health Eur, 37